UNASSIGNED: e16020 Background: To evaluate the 2-year overall survival (OS), cause-specific survival and @entity137 of locally advanced @entity135 @entity1 treated with primary chemo-radiotherapy (CRT) over a two year period. METHODS: Between June 2006 and May 2008, sixty @entity1 with locally advanced @entity135 were treated (excluding skin and thyroid). Of these, seventeen (28.33%) were stage III, thirty nine (65%) were stage IVA and four (6.66%) were stage IVB. All received concurrent 3 weekly @entity900 (75-80 mg/m(2)) and radiotherapy dose of 66-70 Gy in 33-35 fractions, treated daily in three phases by conformal 3-dimensional CT-planning. Treatment response was assessed radiologically 3 months post primary CRT. Survival was calculated from the time of histological diagnosis and time to treatment tailure ( @entity19246 ) from the completion of treatment. RESULTS: The median age was 57 years (range 18-79) and M:F ratio was 3:1.The 2-year OS was 73.3 % and loco-regional control rate was 83.3 %. The treatment failure rate was 16.6 % (10/60 @entity1 ) with a median @entity19246 of 5 months (range= 1 to 24 months). Sixteen @entity1 (26.6%) died with in 2 years of treatment of which five (4%) died of progression from @entity66 , six (4.8%) died of loco-regional recurrence and three (5%) died of distant recurrence. Rest of the three died of other causes and includes two (3.33%) from second @entity2 . The incidence of acute severe or persistent @entity3136 was 4% (RTOG grade 3) and none had grade 3/4 @entity137 . The incidence of late @entity137 was 4% for @entity7190 ( @entity7190 ) of the mandible, 3.2% for severe trismus and 2.4% had sinus/ @entity292 formation. The incidence of severe oropharyngeal stenosis/total @entity1282 was 3.2% and 3 @entity1 (2.4%) were on long term (15-32 months) gastrostomy feeding tube for nutrition. One @entity1 (0.8%) developed severe @entity2998 in the @entity138 field. None of the @entity1 had treatment related @entity204 . CONCLUSIONS: Our results are on par with international standards published in the literature. This data will be followed up for long-term outcomes and can be used as a bench mark for comparison with current modern planning techniques like intensity modulated radiotherapy (IMRT).

Chemoradiotherapy for locally advanced @entity135 : Two-year survival and XXXX outcomes from a regional cancer centre in UK.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer', 'head and neck cancers'] @entity19246 :: ('399', 'Gene') :: ['TTF'] @entity137 :: ('MESH:D064420', 'Disease') :: ['skin toxicity', 'toxicities'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['oral mucositis'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity138 :: ('MESH:C563738', 'Disease') :: ['RT'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2 :: ('MESH:D008175', 'Disease') :: ['primary (lung and oesophageal) cancers'] @entity7190 :: ('MESH:D010025', 'Disease') :: ['ORN', 'osteoradionecrosis'] @entity2998 :: ('MESH:D002340', 'Disease') :: ['carotid artery disease'] @entity292 :: ('MESH:D005402', 'Disease') :: ['fistula'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity137 :: (MESH:D064420,Disease) :: ['toxicity']
